Immutep Limited (YP1A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Immutep Limited (YP1A) has a cash flow conversion efficiency ratio of -0.086x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-11.72 Million ≈ $-13.70 Million USD) by net assets (€136.47 Million ≈ $159.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See YP1A defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Immutep Limited - Cash Flow Conversion Efficiency Trend (2017–2023)
This chart illustrates how Immutep Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Immutep Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Immutep Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huvitz Co. Ltd
KQ:065510
|
-0.009x |
|
Computacenter PLC
LSE:CCC
|
-0.097x |
|
Agile Group Holdings Limited
F:A8P
|
0.153x |
|
Aeon Motor Co Ltd
TWO:1599
|
0.066x |
|
POS Malaysia&Services Holdings Bhd
KLSE:4634
|
-0.005x |
|
Yesil Gayrimenkul Yatirim Ortakligi AS
IS:YGYO
|
0.005x |
|
Sarveshwar Foods Limited
NSE:SARVESHWAR
|
-0.002x |
|
Gotland Rederi AB Series A
ST:GOTL-A
|
0.002x |
Annual Cash Flow Conversion Efficiency for Immutep Limited (2017–2023)
The table below shows the annual cash flow conversion efficiency of Immutep Limited from 2017 to 2023. For the full company profile with market capitalisation and key ratios, see Immutep Limited market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-06-30 | €136.47 Million ≈ $159.55 Million |
€-35.36 Million ≈ $-41.33 Million |
-0.259x | -17.20% |
| 2022-06-30 | €136.76 Million ≈ $159.88 Million |
€-30.23 Million ≈ $-35.34 Million |
-0.221x | +8.19% |
| 2021-06-30 | €73.27 Million ≈ $85.66 Million |
€-17.64 Million ≈ $-20.62 Million |
-0.241x | +26.04% |
| 2020-06-30 | €33.30 Million ≈ $38.93 Million |
€-10.84 Million ≈ $-12.67 Million |
-0.326x | +48.07% |
| 2019-06-30 | €24.39 Million ≈ $28.51 Million |
€-15.29 Million ≈ $-17.87 Million |
-0.627x | -170.19% |
| 2018-06-30 | €33.52 Million ≈ $39.19 Million |
€-7.78 Million ≈ $-9.09 Million |
-0.232x | +27.64% |
| 2017-06-30 | €26.53 Million ≈ $31.02 Million |
€-8.51 Million ≈ $-9.95 Million |
-0.321x | -- |
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more